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Abstract
Purpose: The initial presentation of autoimmune encephalitis (AIE) may resemble other disorders and a comprehensive investiga-
tion is required. In this paper we emphasize the challenges faced by a treating team performing a differential diagnosis and the ne-
cessity for insightful multidisciplinary collaboration.
Case description: We report on the case of a 67-year old man who developed transient disturbances of consciousness in the course 
of  anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis, which was the  first manifestation of  malignant myeloma. 
To our knowledge, this is the first case of anti-NMDAR encephalitis associated with multiple myeloma described in the literature.
Comment: AIE with anti-NMDAR antibodies has become a well-characterised variant of the condition. AIE may or may not be as-
sociated with tumour; therefore it is necessary to use the screening approach for primary malignancy. A proper diagnosis is essential 
in management due to AIE’s potential to respond to immunotherapy and tumour removal if one is present.
Key words:  multiple myeloma, autoimmune encephalitis, anti-NMDAR antibodies, paraneoplastic neurological syndrome.
ISSN: 1230-2813 volume 26 / Issue 1 2017
ADVANCES IN 
PSYCHIATRY & NEUROLOGY
POSTĘPY 
Psychiatrii i Neurologii
CASE REPORT / OPIS PRZYPADKU
Correspondence to/ 
Adres do korespondencji: 
Dr. Anna Stanowska 
Department of Neurology 
5th Military Hospital with Policlinic  
in Cracow 
1-3 Wrocławska St. 
30-901 Cracow, Poland 
phone: +48 662 365 503 
e-mail: anna@stanowski.net
Submitted/Otrzymano: 08.03.2019
Accepted/Przyjęto do druku: 13.03.2019
Adv Psychiatry Neurol 2019; 28 (2): 162-167
DOI: https://doi.org/10.5114/ppn.2019.86259
Streszczenie
Cel: Szerokie spektrum niespecyficznych objawów neuropsychiatrycznych prezentowanych przez osoby z autoimmunologicznym 
zapaleniem mózgu z obecnością przeciwciał anty-NMDAR dość często opóźnia rozpoznanie i implikuje konieczność przeprowa-
dzenia interdyscyplinarnej diagnostyki różnicowej. Celem niniejszej pracy jest przedstawienie opisu przypadku chorego z anty-
-NMDAR autoimmunologicznym zapaleniem mózgu, ze szczególnym uwzględnieniem trudności diagnostycznych.
Opis przypadku: W pracy przedstawiono przypadek 67-letniego mężczyzny z anty-NMDAR autoimmunologicznym zapaleniem 
mózgu, u którego ostre zaburzenia świadomości były pierwszą manifestacją szpiczaka mnogiego. Dotychczas taki związek tych 
jednostek chorobowych nie był opisywany w dostępnych doniesieniach.
Komentarz: Autoimmunologiczne zapalenie mózgu z obecnością przeciwciał anty-NMDAR jest jednym z lepiej scharakteryzowa-
nych typów autoimmunologicznych zapaleń mózgu o stopniowo rosnącej rozpoznawalności i korzystnym potencjale terapeutycz-
nym. W niektórych przypadkach może towarzyszyć chorobie nowotworowej i wyprzedzać jej rozpoznanie, wówczas określane jest 
jako neurologiczny zespół paraneoplastyczny. W procesie diagnostycznym typ zidentyfikowanego przeciwciała może ukierunkować 
dobór badań przesiewowych w celu zlokalizowania pierwotnego procesu nowotworowego.
Słowa kluczowe: szpiczak mnogi, autoimmunologiczne zapalenie mózgu, przeciwciała anty-NMDAR, neurologiczny zespół para-
neoplastyczny.
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PURPOSE 
Autoimmune encephalitis (AIE) comprises a spectrum 
of neurological disorders. It is seeing gradually increasing 
recognition and there is potential for it to respond well 
to treatment. Its clinical presentation, neuroimaging and 
laboratory results may mimic other disorders, which may 
result in a delayed diagnosis as well as late implementation 
of adequate treatment. In some cases AIE may be associ-
ated with malignancy, which is known as paraneoplastic 
autoimmune encephalitis (PAE). The clinical presentation 
of PAE is secondary to the autoimmune reaction triggered 
by the  expression of  specific onconeuronal antigens on 
neoplastic cells, which physiologically occur in the central 
nervous system [1]. Several classes of antibodies have been 
described in association with PAE. The recognition of PAE 
is based on neuroimaging, electroencephalography and ce-
rebrospinal fluid tests, but their specificity and sensitivity 
are limited [2]. The indication of specific onconeuronal an-
tibodies in serum or CSF is crucial in the course of diagno-
sis. The first group of intracellular onconeuronal antibod-
ies typically appears to accompany the tumour. The second 
group of antibodies targeting surface-cell antigens like the 
anti-N-methyl-D-aspartate (anti-NMDAR) antibody are 
less often suspected to have a  paraneoplastic aetiology. 
The  anti-NMDAR encephalitis is one of  the  most com-
prehensively characterised types of AIE, but its wide range 
of  neuropsychiatric symptoms often indicate the  need 
for an   interdisciplinary differential diagnosis. The  aim 
of proper treatment is the removal of the source of the an-
tigens via tumour removal and immunomodulatory thera-
py. The presence of the onconeuronal antibodies indicates 
the need for an extensive tumour search [1].
We report the  case of  a  67-year old man with PAE, 
who was admitted to hospital with rapidly increasing dis-
turbances of consciousness. In the course of differential 
diagnosis the  examination revealed anti-NMDAR anti-
bodies in serum and the patient was diagnosed with mul-
tiple myeloma (MM). To the best of our knowledge, this 
is the  first case of  anti-NMDAR encephalitis associated 
with MM reported in the literature.
CASE REPORT
A 67-year old man, an  academic worker with dia-
betes mellitus and no past psychiatric history, appeared 
at the  emergency unit with acute onset of  impaired con-
sciousness which occurred after awakening. The symptoms 
were preceded by a 4-week course of fever and weight loss 
during which the patient was treated with empirical anti-
biotic therapy due to an upper respiratory tract infection. 
On admission to the  Department of  Neurology, 
the  patient was afebrile and haemodynamically stable. 
There were no other abnormalities found in the neuro-
logical examination aside from disorientation, delirium 
and speech disturbances (aphasia). The basic laboratory 
tests were within normal ranges. The brain computer to-
mography and chest X-ray did not reveal any pathologies. 
Analysis of the cerebrospinal fluid showed increased cy-
tosis (144/3) and protein level (0.97 g/l) with a  normal 
glucose level and negative serum inflammation markers. 
Due to the  suspicion of  encephalitis, empirical intrave-
nous treatment with ceftriaxone and acyclovir was start-
ed during bacteriological testing of  the  CSF. Magnetic 
resonance imaging (MRI) displayed small, diffused areas 
of non-specific demyelisation without restriction of dif-
fusion in the DWI/ADC map or any abnormalities, sug-
gesting herpetic encephalitis. 
On the fourth day of hospitalisation the consciousness 
disturbances retreated. The bacteriological tests of the CSF 
were negative. The  follow-up CSF samples were taken 
on the  eight day of  hospitalisation (blood – iatrogenic). 
Lymphocytic cytosis (627/3) and elevated protein level 
(2.25 g/l) could still be observed. 
The patient was screened for the source of the inflam-
mation. Thyroid and abdominal cavity ultrasound exam-
inations were conducted. The patient was given laryngo-
logical and dental examinations. An unclear change was 
observed in the  panoramic radiograph, localised near 
the right temporomandibular joint. A CT of the jaw was 
made and the patient was seen by a maxillofacial surgeon. 
There were no obvious causes of inflammation.
In the differential diagnosis we took into account vas-
culitis and paraneoplastic syndrome. The follow-up brain 
MRI was similar to the previous one. The magnetic reso-
nance angiography also did not reveal any abnormalities. 
In laboratory tests, Ca 15-3 antigen was slightly increased. 
The remaining common paraneoplastic markers and in-
tracellular onconeuronal antigens were within normal 
ranges. The CSF check-up analysis of cytosis and protein 
levels taken after 2 and 3 weeks of hospitalisation showed 
a slight downward tendency (lymphocytic cytosis 265/3, 
231/3; protein level 0.78 g/l, 0.85 g/l), but they were still 
comparable with the initial level. The intrathecal synthe-
sis of immunoglobulin was identified. The cytology and 
follow-up bacteriological tests remained normal.
Due to the  stable clinical presentation, which did 
not correlate with the  CSF findings, AIE was suspected. 
Anti-NMDAR antibodies were identified in the  patient’s 
serum. Electroencephalography (EEG) showed diffused 
slow waves. The patient was screened for a tumour. Uro-
logical examination, gastroscopy and colonoscopy proved 
irrelevant. A thoraco-abdominal-pelvic CT scan suggested 
lytic metastasis in the skeletal system, which pointed out 
the paraneoplastic aetiology of AIE.
The PET-CT with fluorodeoxyglucose confirmed 
the  lytic metastasis and showed extensive, destructive 
change in. The haematological disorder was taken into ac-
count in the differential diagnosis. Serum protein electro-
phoresis identified a monoclonal spike in the gamma glob-
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ulin fraction with the total protein level within the normal 
range. Immunofixation detected IgG monoclonal protein 
with kappa light chain specificity in the  serum, whereas 
it was absent in the urine. Histopathological examination 
of the sacral mass revealed plasmacytoma, which was con-
firmed by a bone marrow biopsy. 
COMMENT
AIE is a  relatively rare disease but is becoming in-
creasingly better recognised due to the  development 
of diagnostic techniques. Its heterogeneous clinical pre-
sentation may mimic other pathologies of  the  central 
nervous system, implying the  need for insightful inter-
disciplinary investigation and therefore a possible delay 
in proper treatment [3-5].
AIE may be associated with underlying malignan-
cy and, based on the diagnostic criteria of Graus et al., 
can be retrospectively classified as either paraneoplastic 
or non-paraneoplastic syndrome  [6]. The  estimated in-
cidence of neurological paraneoplastic syndromes (NPS) 
is about < 1%. However, more recent data shows that its 
frequency may be higher  [3]. In 2016 new diagnostic 
criteria for autoimmune encephalities were proposed by 
Graus et al. [7].
The neuropsychiatric spectrum of  clinical presenta-
tion of  NPS is an  effect of  autoimmune mediated reac-
tion triggered by the  expression of  onconeuronal anti-
gens on neoplastic cells, which physiologically occurs in 
the CNS [1].
Tumours are usually associated with specific onco-
neuronal antigens, which calls for diagnostic and ther-
apeutic management as well as prognosis. Based on 
the  location of  the  antigens, AIE can be classified into 
two broad groups. Group I (anty-Hu, Yo, Ri, Ma/Ta, 
CV2, GAD, amphisin) targets intracellular antigens and 
shows a  clear predilection to malignancy. The  research 
has displayed its adverse response to immunomodula-
tory treatment and its poor outcome. Group II antibod-
ies directed against cell-surface antigens (anty-NMDA, 
VGKC, VGCC, GABAr, AMPAr, GluR3) less frequently 
accompany malignancy and gives the appearance of bet-
ter responding to treatment. However, the second group 
of antigens was also observed in patients with systemic 
diseases without underlying malignancy as well as after 
viral infection or vaccination [2, 3, 8, 9].
Anti-NMDAR encephalitis has become one of the 
most thoroughly described forms of AIE so far. The first 
report of anti-NMDAR encephalitis was published in 2005 
and until now about 600 cases have been diagnosed [10, 
11]. The  actual incidence of  this disease is unclear, but 
on the basis of an increasing amount of reports it is likely 
that it is more frequent than any other forms of the condi-
tion [12]. Additionally, epidemiological reports have found 
that its incidence exceeds the viral ence phalitis [13]. One 
of  the  retrospective studies among patients in the  18-35 
age range, hospitalized due to encephalitis with unknown 
origin, documented the  anti-NMDAR antibodies in 1% 
cases  [14]. In another multicentre prospective study this 
amount was estimated to be 4% and was found to be second 
most common after acute disseminated encephalomyelitis 
(ADEM) cases of AIE [12, 15]. Anti-NMDAR encephalitis 
mostly involves women (60%) and children (35%), while it 
affects men and elderly people less frequently [4]. 
Clinical and laboratory studies have shown that neu-
ronal dysfunction results from blockage by IgG antibod-
ies and increased internalisation of receptors of the extra-
cellular epitope region located in the N-terminal domain 
of the NR1 subunit of the NMDA. This pathomechanism is 
reversible [2, 16-18]. The antibodies can be detected both in 
serum and CSF, though researchers have proved that CSF 
tests have better sensitivity and specificity [19]. The clini-
cal effect of NMDAR antibodies is similar to the pharma-
cological impact of ketamine or phencyclidine, which are 
called dissociative anaesthetics [16]. The clinical symptoms 
correlate with the location of NMDAR in the hippocam-
pus, the brain cortex and the amygdaloid nucleus.
On the basis of the criteria of Graus et al., the disease 
can be classified as either “probable” or “definite” anti- 
NMDAR encephalitis [7].
The typical course of  anti-NMDAR AIE is subacute 
and progressive, with fluctuations of  the  neuropsycho-
logical state  [4]. The  initial symptoms are nonspecific. 
In 50-70% of cases prodromal viral-like symptoms such 
as fever, nausea, diarrhoea and upper respiratory tract 
disorder occur and within days are followed by a  wide 
range of  psychiatric (behaviour disturbances, catatonia, 
delusions, psychosis) and neurological (cognitive impair-
ment, language disintegration, seizures, oro-lingual dys-
kinesias, limb and trunk choreoathetosis, opisthotonic 
postures) manifestations, which may lead to disturbances 
of consciousness and a state of unresponsiveness. A prob-
lem with speaking, with its initial impoverishment, echo-
lalia and echopraxia leading to mutism in its later stages, 
cannot be classified as cortical aphasia. Some patients de-
velop central hypoventilation and autonomic instability 
(hyperthermia, tachycardia, hypersalivation, hyperten-
sion, bradycardia, hypotension, urinary incontinence, 
erectile dysfunction) and need to be managed in inten-
sive care units [2, 8, 9, 12, 20].
Evidence from the research shows that there are dif-
ferences in the  early phase of  the  disease between chil-
dren and adults. The  most of  elderly patients present 
psychiatric disturbances in the initial presentation of an-
ti-NMDAR encephalitis. Rarely, the psychosis, as well as 
abnormal movement or seizures, can be the isolated epi-
sodes that may result in a misdiagnosis and admission to 
psychiatric facilities  [10, 21]. By contrast, children tend 
to present movement disturbances or seizures. In fewer 
than 4% of  cases the  course of  the  disease was mono-
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symptomatic  [2, 8, 9, 20]. A  cohort study revealed that 
among patients older than 45 years anti-NMDAR AIE 
affects men more often than women, and that its course is 
milder, which causes a delay in recognition and treatment 
implementation [22].
The brain MRI in anti-NMDAR AIE can be either nor-
mal or may show nonspecific demyelination. In 65-80% 
cases T2 and FLAR signal hyperintensivity has been ob-
served in the medial temporal lobes, the cerebellar or ce-
rebral cortex, the basal ganglia and the brainstem, and in 
rare cases the spinal cord. These changes may present subtle 
contrast enhancement. The  follow-up brain MRI may be 
normal or may reveal brain atrophy [2, 5, 8, 12, 23].
Recent studies carried out using positive emission 
tomography with fluorodeoxyglucose (FDG-PET) have 
identified some characteristic patterns for anti-NMDAR 
encephalitis. Hypermetabolism in the  frontal and tem-
poral lobes, in contrast to relative hypometabolism in 
the  occipital lobes of  the  cerebral glucose metabolism, 
has been observed. What is more, the  reports suggest-
ed a  correlation between disease severity and a  return 
to normality after recovery. Another piece of  research 
based on single-photon emission computed tomography 
(SPECT) showed distinctive, multifocal cortical and sub-
cortical changes of variable character during the course 
of the disease. In some cases these changes may be absent 
in the early stages [8, 12, 24].
Electroencephalography (EEG) in patients with anti- 
NMDAR encephalitis is estimated to be abnormal in more 
than 90% cases. Usually EEG shows diffused slow waves 
and disorganised activity with less common foci of the ep-
ileptic activity. Some patients present a pattern unique for 
anti-NMDAR encephalitis, referred to as extreme delta 
brush (EDB) due to the  rhythmic activity of  delta-theta 
waves with superimposed bursts of rhythmic beta frequen-
cy activity. Reports suggested that the characteristic pattern 
was associated with longer hospitalisation and a poorer out-
come. It was observed especially among patients in coma 
and was not modified by antiepileptic drugs [2, 4, 12, 25].
The CSF examination reveals abnormalities in 80% 
patients in the early stages of  the disease. Most AIE are 
associated with the  presence of  mild-to-moderate lym-
phocytic pleocytosis and an increased protein concentra-
tion level. Less frequently, oligoclonal bands are detected.
The identification of onconeuronal antibodies in se-
rum or CSF is crucial in the diagnosis of AIE. Consider-
ing the  limitations of a  laboratory investigation, the  re-
sults must be interpreted individually based on clinical 
presentation. Research shows that the  sensitivity and 
specificity of CSF tests are better than the serum ones. It is 
important to distinguish between particular classes of im-
munoglobulin, especially IgG, IgM and IgA. The presence 
of antibodies in the IgG class of immunoglobulin is char-
acteristic for anti-NMDAR encephalitis. IgM and IgA 
anti-NMDAR antibodies have been identified in patients 
with schizophrenia and also in 10% of  cases of  healthy 
individuals, whereas IgG anti-NMDAR antibodies were 
not detected [4, 8, 9].
The identification of  the  onconeuronal antibod-
ies signals the  need for an  extensive tumour screening. 
The  selection of  diagnostic methods is made according 
to the  class of  antibodies detected and the  patient’s age 
and sex [5].
Anti-NMDAR encephalitis predominates in women in 
the 12-45 age range (53%) and in most cases ovarian tera-
toma has been identified (94%). A lower percentage of ma-
lignancy was detected among patients older than 45 years. 
In the  second group, teratomas in other locations were 
more often observed as well as lung, breast, testis, thymus, 
pancreas and ovarian tumours. Men and children younger 
than 12 years old are affected in about 6% cases [2]. 
The case described here is the first reported in literature 
with anti-NMDAR encephalitis during the course of mul-
tiple myeloma. We found that  two cases of  stiff-person 
syndrome associated with presence of the anti-GAD anti-
bodies in multiple myeloma have been described [26, 27].
Diagnosis of malignancy is relevant due to the follow-
ing aspects:
1. Adequate tumour therapy allows treatment of  auto-
immune encephalitis.
2. Oncological and immunomodulatory treatments may 
demand a fixed scheme.
3. The implementation of  treatment in AIE (cortico-
steroids, rituximab or cyclophosphamide) prior to 
the recognition of malignancy may delay the proper 
diagnosis and targeted treatment [8].
The European Federation of  Neurological Scienc-
es (EFNS) recommends a  selection of  screening tests on 
the  basis of  the  onconeuronal antibodies detected and 
the sex of the patient. Due to the high probability of ovar-
ian teratoma, transvaginal ultrasound is the investigation 
of first choice, followed by CT or MRI of the abdomen and/
or pelvic region. In young women the  CT examination 
should not be conducted due to the high doses of radia-
tion. The screening tests for breast tumour are mammog-
raphy and then MRI. The whole body FDG-PET is usual-
ly negative in a patient with ovarian teratoma, whereas it 
can be helpful in a case of thymoma or lung tumour with 
normal thorax CT. When a testicular tumour is suspected 
an ultrasound and then CT of the pelvic region should be 
made. According to the  recommendations, patients with 
a negative primary screening should undergo screenings 
for tumour in 6-month periods for 2-4 years. The guide-
lines do not include any indications for lymphoma, small 
cell lung carcinoma or neuroblastoma due to the  inade-
quate number of cases diagnosed, which do not for the for-
mulation of recommendations [2, 28].
Anti-NMDAR encephalitis has a characteristic but non-
specific clinical picture; there is no pathognomic symptom, 
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which would result in a wide interdisciplinary diagnostic 
process. 
Usually, within the first weeks of the disease the em-
pirical antibiotic and/or antiviral therapy is implemented, 
as in our case. Here, bacteriological aetiology was ruled 
out due to the negative bacteriological tests of the blood 
samples and CSF. The PCR examination seeking to estab-
lish the presence of HSV in CSF proved the high sensitiv-
ity and specificity. However, it might remain false-neg-
ative within the  first 24 hours of  symptoms. An  HSV 
aetiology was excluded on the basis of the normal results 
of the CSF/serum index for HSV, lack of changes typical 
for herpetic encephalitis in a double-checked brain MRI 
and persistent abnormal CSF results despite the  treat-
ment implemented. The HHV-6 viral infection can cause 
limbic encephalitis in immunocompromised patients. 
Our patient was immunocompetent, thus HHV-6 en-
cephalitis was unlikely.
The reasons for the  prodromal viral-like period in 
anti-NMDAR encephalitis remains unclear. One piece 
of clinical research revealed that a viral aetiology is un-
likely due to the negative results of insightful CSF analy-
sis, brain biopsy and tests for infection [18]. At the same 
time, a  recently conducted study has shown that an-
ti-NMDAR encephalitis appeared in patients who had 
suffered from herpetic encephalitis 2-6 weeks earlier [23].
In differential diagnosis acute disseminated enceph-
alomyelitis (ADEM) should also be taken into consider-
ation. It is characterised by diffused demyelinating foci 
in the  central nervous system. In some cases it affects 
the  optic nerves and the  spinal cord. These symptoms 
were not observed in the reported case.
Vasculitis of the central nervous system may resemble 
AIE in some cases and confirming it in with neuroim-
aging shows the necessity of an exploration for systemic 
diseases.
Patients with systemic lupus erythematosus may also 
present an  acute onset of  neuropsychiatric symptoms. 
However, reports indicate that in most cases these symp-
toms coexist with an acute phase of a problem in another 
organ or systemic disease.
Encephalitis may be the  first manifestation of  CSN 
lymphoma or carcinomatous meningitis. Therefore 
the  repetitive cytology of  CSF and screening tests may 
help in proper diagnosis [2, 8].
Rapidly progressive neuropsychiatric disturbances sus-
pected to be Creutzfeldt-Jacob disease (CJD) should also be 
distinguished from AIE. There have been reports suggest-
ing the presence of anti-NMDAR antibodies in the serum 
of some patients with CJD. However, another multicentre 
study did not detect the presence of anti-NMDAR antibod-
ies in CSF among patients with pathologically confirmed 
CJD. Additionally, in patients with anti-NMDAR enceph-
alitis the 14-3-3 protein was not identified in the CSF [29].
The aim of  proper treatment of  NPS is the  removal 
of  the  source of  antigens by targeted ontological treat-
ment and immunotherapy  [1]. Corticosteroids, intra-
venous immunoglobulin and/or plasma exchange form 
the first line of immunotherapy. The second line of treat-
ment is rituximab and/or cyclophosphamide. Clinical re-
search among patients in the 1-85 age range revealed that 
immunotherapy combined with tumour resection was 
associated with a  substantial neurological improvement 
in 81% of cases  [11]. Furthermore, a better response to 
immunomodulating treatment was observed in patients 
with tumour resection and the second line therapy was 
less frequently implemented in comparison with patients 
without the associated malignancy [12]. 
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